Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease

 Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease

Engitix and Morphic Collaborate to Detect ECM-Related Targets in Fibrostenotic Inflammatory Bowel Disease

Shots:

  • The collaboration will deploy Engitix’s ECM platform to identify drug targets for potential future oral integrin drug therapies as treatments for fibrostenotic diseases
  • The ECM platform will be used to characterize the expression of drug therapies and cover integrin/ non-integrin expression in fibrostenosis. Morphic will advance therapies for patients with autoimmune, CV, metabolic diseases, as well as fibrosis and cancer by leveraging its MInT technology
  • The collaboration will lead towards the expansion of ECM platform by exploring disease indications beyond Engitix in-house programmes, Additionally, Morphic is advancing its pipeline and discovery activities utilizing its MInT technology in collaboration with AbbVie, Janssen and Schrödinger

Click here to­ read full press release/ article | Ref: Businesswire | Image: Engitix

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post